KROS logo

KROS
Keros Therapeutics Inc

1,223
Mkt Cap
$238.84M
Volume
394,560.00
52W High
$22.55
52W Low
$10.42
PE Ratio
6.63
KROS Fundamentals
Price
$12.07
Prev Close
$11.64
Open
$11.60
50D MA
$11.63
Beta
0.89
Avg. Volume
334,025.01
EPS (Annual)
$2.30
P/B
0.78
Rev/Employee
$3.13M
$500.28
Loading...
Loading...
News
all
press releases
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts
Shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have earned a consensus rating of "Hold" from the nine analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and four ha...
MarketBeat·9d ago
News Placeholder
More News
News Placeholder
Keros Therapeutics (KROS) to Release Quarterly Earnings on Tuesday
Keros Therapeutics (NASDAQ:KROS) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at...
MarketBeat·13d ago
News Placeholder
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and Takeda progress, that could reshape investor sentiment.
Zacks·21d ago
News Placeholder
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?
Keros reshaped its finances with a Takeda deal, boosting revenue and cutting R&D ??? but does it truly reduce dilution risk as 2026 uncertainty looms?
Zacks·21d ago
News Placeholder
KROS Rinvatercept: What to Know Before DMD Phase II Starts
KROS sharpens focus on rinvatercept as a phase II DMD study looms in 2026, shifting the story toward execution and high-stakes clinical catalysts.
Zacks·21d ago
News Placeholder
Keros Therapeutics (NASDAQ:KROS) Director Purchases $11,700.00 in Stock
Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) Director Jean Jacques Bienaime acquired 1,000 shares of Keros Therapeutics stock in a transaction dated Wednesday, April 15th. The stock was...
MarketBeat·23d ago
News Placeholder
Keros Therapeutics (NASDAQ:KROS) Director Acquires $11,700.00 in Stock
Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) Director Jean Jacques Bienaime bought 1,000 shares of the firm's stock in a transaction dated Wednesday, April 15th. The stock was acquired at...
MarketBeat·24d ago
News Placeholder
Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Down 24.9% in March
Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the recipient of a large decrease in short interest in March. As of March 31st, there was short interest totaling 1,494,814 shares, a...
MarketBeat·25d ago
News Placeholder
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Hold" from Analysts
Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the ten analysts that are presently covering the stock, Marketbeat Ratings...
MarketBeat·1mo ago
News Placeholder
Keros Therapeutics, Inc. $KROS Shares Acquired by SG Americas Securities LLC
SG Americas Securities LLC lifted its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 1,420.6% in the fourth quarter, according to its most recent Form 13F filing with the...
MarketBeat·1mo ago
<
1
2
...
>

Latest KROS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.